Cargando…

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist

Gonadotropin-releasing hormone (GnRH) agonist has been used in the treatment of a wide variety of sex-hormone-related diseases, as the administration of GnRH agonist can alter the secretion of gonadotropin and sex hormones. Recently, we found that the long-acting GnRH agonist aggravated hyperthyroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Eun Jin, Song, Ha Do, Yang, Ji Hoon, Park, So Young, Kim, Sung Hoon, Yoon, Hyun Koo, Yim, Chang Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811697/ https://www.ncbi.nlm.nih.gov/pubmed/24396682 http://dx.doi.org/10.3803/EnM.2013.28.3.221

Ejemplares similares

Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
por: Marin, Loris, et al.
Publicado: (2022)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty
por: Lee, Ji Woo, et al.
Publicado: (2014)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis
por: Gocho, Naoki, et al.
Publicado: (2018)

Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020)

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis
por: Lee, Dong-Yun, et al.
Publicado: (2016)

Single-dose administration of a short-acting gonadotropin-releasing hormone agonist does not affect cycle outcome in frozen–thawed embryo transfer cycles
por: Wang, Hanbi, et al.
Publicado: (2021)

Gonadotropin-releasing hormone agonist triggering with concomitant administration of low doses of human chorionic gonadotropin or a freeze-all strategy in high responders
por: Karacan, Meric, et al.
Publicado: (2017)

Live births from in vitro fertilization-embryo transfer following the administration of gonadotropin-releasing hormone agonist without gonadotropins: Two case reports
por: Li, Mai, et al.
Publicado: (2023)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
por: Yoon, Jong Wan, et al.
Publicado: (2017)

Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment
por: Barbosa, Mariana, et al.
Publicado: (2020)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

The Influence of Gonadotropin-Releasing Hormone Agonist Treatment on Thyroid Function Tests in Children with Central Idiopathic Precocious Puberty
por: Naderi, Fariba, et al.
Publicado: (2019)

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization
por: Kwon, Su-Kyoung, et al.
Publicado: (2013)

Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis
por: Zheng, Fei, et al.
Publicado: (2019)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

Evaluation of uterine receptivity after gonadotropin releasing hormone agonist administration as an oocyte maturation trigger: a rodent model
por: Ezoe, Kenji, et al.
Publicado: (2019)

Effect of duration of gonadotropin releasing hormone agonist on the outcome of in vitro fertilization-embryo transfer in a short-acting long regimen
por: MU, Zhen-Ni, et al.
Publicado: (2019)

Pregnancy outcome in long- versus short-acting gonadotropin-releasing hormone agonist cycles in participants with normal ovarian reserve: An RCT
por: Kabodmehri, Roya, et al.
Publicado: (2023)

Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats
por: YAMAMURA, Takashi, et al.
Publicado: (2014)

Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty
por: Lee, Hae Sang, et al.
Publicado: (2018)

SAT-304 Unexplained Asymptomatic Hyperestrogenism in Central Precocious Puberty Patient Treated with Gonadotropin Releasing Hormone Agonist
por: Kim, Dae Hyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s76grbacik7niemhj317snqbia